After a punishing 61% decline in its share price over the past year, Atlassian finds itself at a critical juncture. With the stock trading near $118, investors are grappling with whether this represents a profound disconnect from long-term potential or a justified reassessment of growth prospects in a shifting market.
A Goodyear, Arizona woman's attempt to fix her TV's closed captioning spiraled into a six-month ordeal, culminating in the loss of her life savings. This case highlights the sophisticated tactics of modern fraudsters and a dramatic surge in high-dollar scams targeting older adults.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
In a volatile market, certain low-priced Asian stocks are drawing attention not just for their valuation, but for underlying financial strength. We examine three such companies—from healthcare in New Zealand to property services in Greater China—that defy the typical 'penny stock' stereotype with solid fundamentals.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Across India's villages and small towns, a new generation of workers is logging on after sunset to label the data that trains the world's most advanced AI systems. This quiet workforce, many of them women and first-generation graduates, is finding economic opportunity while reshaping global tech's supply chain.
After Abbott Laboratories' stock plunged nearly 10% on disappointing revenue, CEO Robert B. Ford made a significant personal investment, purchasing $2 million in company shares. This move, seen as a strong signal of insider confidence, highlights a clash between short-term market jitters and long-term corporate strategy.
As the U.S. Department of Defense advances its layered 'Golden Dome' missile defense concept, aerospace and defense giant RTX Corporation emerges with a commanding portfolio of existing, scalable systems—from Patriot interceptors to advanced radars—positioning it for sustained growth amid heightened global security demands.
Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
While aggressively deploying AI across its vast logistics network, FedEx is taking a measured, pilot-stage approach to warehouse automation and drones, CEO Raj Subramaniam tells The New York Times. The shipping giant, handling $2 trillion in global commerce, prioritizes scalable infrastructure over unproven robotics for its 17 million daily packages.
InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.
While Winter Storm Devin triggered JetBlue's late-December collapse, a closer look reveals a fragile operational system, concentrated network, and strained labor relations that pose significant ongoing risks for the airline and its investors.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Amid widespread anxiety over AI-driven job losses, a new report from the Yale Budget Lab finds little evidence of large-scale labor market disruption, raising questions about whether 'AI-washing' is being used to justify corporate layoffs.
Ford Motor and Chinese tech giant Xiaomi have firmly denied a Financial Times report of preliminary talks to collaborate on electric vehicle production in the U.S., even as Ford's CEO publicly admires and studies Chinese EV technology while labeling it a major competitive threat.
Elon Musk has formally merged his rocket company SpaceX with artificial intelligence firm xAI, a strategic consolidation aimed at creating a vertically integrated powerhouse focused on AI and space infrastructure, according to an internal memo obtained by Business Insider.
IDEXX Laboratories announces a planned CEO transition for 2026 alongside the launch of its flagship AI veterinary imaging platform, signaling a dual focus on leadership continuity and technological innovation in the competitive animal health diagnostics market.
The latest release of court documents linked to Jeffrey Epstein has intensified scrutiny on the British establishment, implicating a disgraced royal, a former duchess, and a senior Labour figure in the financier's orbit.
The Bureau of Labor Statistics has postponed the release of January's highly anticipated employment data due to a partial federal funding lapse, marking the latest economic disruption from Washington's budget impasse.
A partial government shutdown has forced the Bureau of Labor Statistics to postpone the critical January jobs report, leaving Federal Reserve policymakers without a key dataset as they weigh potential interest rate cuts ahead of their March meeting.
